EXHIBIT 99.2
Supernus to Attend FBR HealthCare Conference in September
Rockville, MD, August 19, 2014 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will be hosting investor meetings during the FBR Healthcare Conference.
Date: Wednesday, September 3
Place: Four Seasons Hotel, Boston
Investors interested in arranging a meeting during this conference should contact the FBR meeting coordinator.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591
or
Investor Contact:
Cockrell Group
877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com
